Lanreotide vs PT-141
Overview
Lanreotide and PT-141 are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Lanreotide and PT-141 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Lanreotide | PT-141 | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 60-120 mg | 1.75 mg |
| Frequency | every 4 weeks | as needed |
| Reported benefits | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones | Enhanced libido, improved sexual function, arousal support |
| Reported side effects | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases | Nausea, flushing, blood pressure changes |
Key differences
Primary use. Lanreotide is categorised under Hormonal, while PT-141 falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Lanreotide: FDA-approved. PT-141: FDA-approved.
Dosing. Lanreotide is typically dosed at 60-120 mg (every 4 weeks). PT-141 is typically dosed at 1.75 mg (as needed).
Can you stack them?
Some protocols combine peptides, but stacking Lanreotide and PT-141 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Lanreotide and PT-141?
- Lanreotide and PT-141 are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. Lanreotide is FDA-approved for one or more indications, whereas PT-141 is FDA-approved for one or more indications.
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- What is PT-141 used for?
- Sexual function peptide.
- Can you take Lanreotide and PT-141 together?
- Some users combine peptides within a single protocol, but stacking Lanreotide and PT-141 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Lanreotide or PT-141 FDA-approved?
- Lanreotide is FDA-approved for one or more indications. PT-141 is FDA-approved for one or more indications.
Read the full articles
- Lanreotide — full monograph: mechanism, research, dosing & references
- PT-141 — full monograph: mechanism, research, dosing & references